bIosimilar of aDalimumab, an European evAluation

UnknownOBSERVATIONAL
Enrollment

1,050

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2024

Conditions
Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisCrohn DiseaseUlcerative Colitis
Sponsors

Lead Sponsor

All Listed Sponsors
lead

Fresenius Kabi

INDUSTRY

NCT05190484 - bIosimilar of aDalimumab, an European evAluation | Biotech Hunter | Biotech Hunter